 Amyotrophic Lateral Sclerosis
"Amyotrophic Lateral Sclerosis" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A degenerative disorder affecting upper MOTOR NEURONS in the brain and lower motor neurons in the brain stem and SPINAL CORD. Disease onset is usually after the age of 50 and the process is usually fatal within 3 to 6 years. Clinical manifestations include progressive weakness, atrophy, FASCICULATION, hyperreflexia, DYSARTHRIA, dysphagia, and eventual paralysis of respiratory function. Pathologic features include the replacement of motor neurons with fibrous ASTROCYTES and atrophy of anterior SPINAL NERVE ROOTS and corticospinal tracts. (From Adams et al., Principles of Neurology, 6th ed, pp1089-94)
| Descriptor ID |
D000690
|
| MeSH Number(s) |
C10.228.854.139 C10.574.562.250 C10.574.950.050 C10.668.467.250 C18.452.845.800.050
|
| Concept/Terms |
Amyotrophic Lateral Sclerosis- Amyotrophic Lateral Sclerosis
- Lateral Scleroses, Amyotrophic
- Sclerosis, Amyotrophic Lateral
- Gehrig's Disease
- Gehrig Disease
- Gehrigs Disease
- Lou Gehrig Disease
- Lou-Gehrigs Disease
- Disease, Lou-Gehrigs
- Motor Neuron Disease, Amyotrophic Lateral Sclerosis
- ALS (Amyotrophic Lateral Sclerosis)
- Lou Gehrig's Disease
Amyotrophic Lateral Sclerosis, Guam Form- Amyotrophic Lateral Sclerosis, Guam Form
- Amyotrophic Lateral Sclerosis-Parkinsonism-dementia Complex 1
- Amyotrophic Lateral Sclerosis Parkinsonism dementia Complex 1
- Amyotrophic lateral sclerosis, Parkinsonism-Dementia complex of Guam
- Amyotrophic lateral sclerosis, Parkinsonism Dementia complex of Guam
- Guam Disease
- Disease, Guam
- Guam Form of Amyotrophic Lateral Sclerosis
|
Below are MeSH descriptors whose meaning is more general than "Amyotrophic Lateral Sclerosis".
Below are MeSH descriptors whose meaning is more specific than "Amyotrophic Lateral Sclerosis".
This graph shows the total number of publications written about "Amyotrophic Lateral Sclerosis" by people in this website by year, and whether "Amyotrophic Lateral Sclerosis" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1980 | 1 | 0 | 1 | | 1981 | 0 | 1 | 1 | | 1982 | 3 | 0 | 3 | | 1989 | 1 | 0 | 1 | | 1990 | 1 | 0 | 1 | | 1991 | 2 | 0 | 2 | | 1992 | 1 | 1 | 2 | | 1993 | 5 | 0 | 5 | | 1994 | 3 | 1 | 4 | | 1995 | 6 | 0 | 6 | | 1996 | 4 | 1 | 5 | | 1997 | 4 | 2 | 6 | | 1998 | 2 | 1 | 3 | | 1999 | 1 | 1 | 2 | | 2000 | 1 | 2 | 3 | | 2001 | 3 | 0 | 3 | | 2002 | 1 | 0 | 1 | | 2003 | 3 | 0 | 3 | | 2004 | 4 | 0 | 4 | | 2005 | 1 | 1 | 2 | | 2007 | 0 | 1 | 1 | | 2008 | 2 | 0 | 2 | | 2009 | 4 | 1 | 5 | | 2010 | 4 | 2 | 6 | | 2011 | 6 | 0 | 6 | | 2012 | 3 | 0 | 3 | | 2013 | 4 | 0 | 4 | | 2014 | 4 | 0 | 4 | | 2015 | 2 | 0 | 2 | | 2016 | 1 | 1 | 2 | | 2017 | 4 | 2 | 6 | | 2018 | 4 | 0 | 4 | | 2019 | 2 | 1 | 3 | | 2020 | 2 | 1 | 3 |
To return to the timeline, click here.
Below are the most recent publications written about "Amyotrophic Lateral Sclerosis" by people in Profiles.
-
Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Rossing P, Kolkhof P, Nowack C, Schloemer P, Joseph A, Filippatos G. Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. N Engl J Med. 2020 12 03; 383(23):2219-2229.
-
Tabor-Gray L, Vasilopoulos T, Plowman EK. Differences in voluntary and reflexive cough strength in individuals with amyotrophic lateral sclerosis and healthy adults. Muscle Nerve. 2020 11; 62(5):597-600.
-
Chapin JL, Gray LT, Vasilopoulos T, Anderson A, DiBiase L, York JD, Robison R, Wymer J, Plowman EK. Diagnostic utility of the amyotrophic lateral sclerosis Functional Rating Scale-Revised to detect pharyngeal dysphagia in individuals with amyotrophic lateral sclerosis. PLoS One. 2020; 15(8):e0236804.
-
Ghadge GD, Sonobe Y, Camarena A, Drigotas C, Rigo F, Ling KK, Roos RP. Knockdown of GADD34 in neonatal mutant SOD1 mice ameliorates ALS. Neurobiol Dis. 2020 03; 136:104702.
-
Araki K, Araki A, Honda D, Izumoto T, Hashizume A, Hijikata Y, Yamada S, Iguchi Y, Hara A, Ikumi K, Kawai K, Ishigaki S, Nakamichi Y, Tsunekawa S, Seino Y, Yamamoto A, Takayama Y, Hidaka S, Tominaga M, Ohara-Imaizumi M, Suzuki A, Ishiguro H, Enomoto A, Yoshida M, Arima H, Muramatsu SI, Sobue G, Katsuno M. TDP-43 regulates early-phase insulin secretion via CaV1.2-mediated exocytosis in islets. J Clin Invest. 2019 07 29; 129(9):3578-3593.
-
Dzhashiashvili Y, Monckton CP, Shah HS, Kunjamma RB, Popko B. The UPR-PERK pathway is not a promising therapeutic target for mutant SOD1-induced ALS. Neurobiol Dis. 2019 07; 127:527-544.
-
Tabor-Gray LC, Gallestagui A, Vasilopoulos T, Plowman EK. Characteristics of impaired voluntary cough function in individuals with amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2019 02; 20(1-2):37-42.
-
Plowman EK, Tabor-Gray L, Rosado KM, Vasilopoulos T, Robison R, Chapin JL, Gaziano J, Vu T, Gooch C. Impact of expiratory strength training in amyotrophic lateral sclerosis: Results of a randomized, sham-controlled trial. Muscle Nerve. 2019 01; 59(1):40-46.
-
Ghadge GD, Kay BK, Drigotas C, Roos RP. Single chain variable fragment antibodies directed against SOD1 ameliorate disease in mutant SOD1 transgenic mice. Neurobiol Dis. 2019 01; 121:131-137.
-
Riehm JJ, Wang L, Ghadge G, Teng M, Correa AM, Marks JD, Roos RP, Allen MJ. Poloxamer 188 decreases membrane toxicity of mutant SOD1 and ameliorates pathology observed in SOD1 mouse model for ALS. Neurobiol Dis. 2018 07; 115:115-126.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|